GSK announces sale of its remaining stake in Aspen
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number: 1985/0002935/06
Share code: APN
(“Aspen” or “the Company”)
GSK ANNOUNCES SALE OF ITS REMAINING STAKE IN ASPEN
GlaxoSmithKline (“GSK”) has confirmed that, in accordance with its stated intention, it has successfully
completed an accelerated bookbuild for the disposal of its remaining shareholding in Aspen (28.2 million
ordinary shares or 6.2% of the Company’s issued share capital) conducted after the market closed
The disposal in no way affects the ongoing collaboration between Aspen and GSK in South Africa and a
number of other trading relationships between the two companies. David Redfern, GSK’s chief strategy
officer, will remain a member of the Aspen board of directors.
Stephen Saad, the Aspen Group Chief Executive, said “Aspen’s exceptional relationship with GSK and the
many mutually beneficial trading activities between the companies remain unaffected by this disposal. We
are pleased that Aspen shareholders are relieved of the uncertainty caused by GSK’s stated intention to
dispose of its interests, which eliminates the overhang caused by this uncertainty.”
29 September 2016
Investec Bank Limited
Date: 29/09/2016 09:05:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.